380 related articles for article (PubMed ID: 17928625)
1. Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study.
Schindler C; Mueller A; Bramlage P; Boecking W; Kirch W; Schweizer J
Angiology; 2007 Dec-2008 Jan; 58(6):710-6. PubMed ID: 17928625
[TBL] [Abstract][Full Text] [Related]
2. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions.
Dick P; Wallner H; Sabeti S; Loewe C; Mlekusch W; Lammer J; Koppensteiner R; Minar E; Schillinger M
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1090-5. PubMed ID: 19859954
[TBL] [Abstract][Full Text] [Related]
3. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.
Schillinger M; Sabeti S; Loewe C; Dick P; Amighi J; Mlekusch W; Schlager O; Cejna M; Lammer J; Minar E
N Engl J Med; 2006 May; 354(18):1879-88. PubMed ID: 16672699
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Koppensteiner R; Spring S; Amann-Vesti BR; Meier T; Pfammatter T; Rousson V; Banyai M; van der Loo B
J Vasc Surg; 2006 Dec; 44(6):1247-53. PubMed ID: 17145426
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Radke PW; Figulla HR; Drexler H; Klues HG; Mügge A; Silber S; Daniel W; Schmeisser A; Reifart N; Motz W; Büttner HJ; Fischer D; Ortlepp JR; Schaefers K; Hoffmann R; Hanrath P;
Am Heart J; 2006 Oct; 152(4):761.e1-6. PubMed ID: 16996855
[TBL] [Abstract][Full Text] [Related]
6. Successful lower extremity angioplasty improves brachial artery flow-mediated dilation in patients with peripheral arterial disease.
Husmann M; Dörffler-Melly J; Kalka C; Diehm N; Baumgartner I; Silvestro A
J Vasc Surg; 2008 Nov; 48(5):1211-6. PubMed ID: 18771886
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study.
Nylaende M; Kroese AJ; Morken B; Stranden E; Sandbaek G; Lindahl AK; Arnesen H; Seljeflot I
Vasc Med; 2007 Nov; 12(4):275-83. PubMed ID: 18048463
[TBL] [Abstract][Full Text] [Related]
8. Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty : a randomised, placebo-controlled trial.
Schindler C; Schweizer J; Müller A; Koch R; Hellner G; Fuchs W; Kirch W
Clin Drug Investig; 2005; 25(2):89-97. PubMed ID: 17523758
[TBL] [Abstract][Full Text] [Related]
9. Trials of endovascular treatment for superficial femoral artery occlusive lesions: a call for medically managed control patients.
Wilson SE
Ann Vasc Surg; 2010 May; 24(4):498-502. PubMed ID: 20036508
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
11. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting.
Schillinger M; Sabeti S; Dick P; Amighi J; Mlekusch W; Schlager O; Loewe C; Cejna M; Lammer J; Minar E
Circulation; 2007 May; 115(21):2745-9. PubMed ID: 17502568
[TBL] [Abstract][Full Text] [Related]
12. Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: a randomized trial.
Ansel GM; Silver MJ; Botti CF; Rocha-Singh K; Bates MC; Rosenfield K; Schainfeld RM; Laster SB; Zander C
Catheter Cardiovasc Interv; 2006 Feb; 67(2):288-97. PubMed ID: 16408299
[TBL] [Abstract][Full Text] [Related]
13. Selective stenting in subintimal angioplasty: analysis of primary stent outcomes.
Schmieder GC; Richardson AI; Scott EC; Stokes GK; Meier GH; Panneton JM
J Vasc Surg; 2008 Nov; 48(5):1175-80; discussion 1180-1. PubMed ID: 18778911
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
15. The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial--a multicenter study of AT1-receptor blocker therapy in coronary stenting.
Krämer J; Ruf RG; Schmidt S; Axthelm C; Strasser R; Janssen G; Thieme T; Kusch A; Waigand J; Dietz R; Gross CM
J Invasive Cardiol; 2008 May; 20(5):205-10. PubMed ID: 18460701
[TBL] [Abstract][Full Text] [Related]
16. Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention.
Okimoto T; Imazu M; Hayashi Y; Gomyo Y; Sekiguchi Y; Yanagihara K; Shimohara Y; Sumii K; Yamamoto H; Tadehara F; Toyofuku M; Kohno N
Cardiovasc Drugs Ther; 2001 Jul; 15(4):323-9. PubMed ID: 11800416
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.
Yoshida O; Hirayama H; Nanasato M; Watanabe T; Murohara T
Am Heart J; 2005 Jan; 149(1):e2. PubMed ID: 15660025
[TBL] [Abstract][Full Text] [Related]
18. Effect of quinapril on in-stent restenosis and relation to plasma apoptosis signaling molecules.
Deftereos S; Giannopoulos G; Kossyvakis C; Kaoukis A; Raisakis K; Driva M; Panagopoulou V; Lappos S; Rentoukas I; Pyrgakis V; Alpert MA
Am J Cardiol; 2010 Jan; 105(1):54-8. PubMed ID: 20102890
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous revascularization of femoropopliteal artery disease: PTA and PTA plus stent. Results after six years' follow-up.
Pozzi Mucelli F; Fisicaro M; Calderan L; Malacrea M; Mazzone C; Cattin L; Scardi S; Pozzi Mucelli R
Radiol Med; 2003 Apr; 105(4):339-49. PubMed ID: 12835627
[TBL] [Abstract][Full Text] [Related]
20. [Doppler sonography diagnosis of restenosis after percutaneous transluminal angioplasty: sensitivity and specificity of the pedal-brachial index in relation to changes in absolute arterial blood pressure].
Radak Dj; Laps KH; Jeger KA; Ilijevski N; Vojić M
Srp Arh Celok Lek; 1998; 126(3-4):83-91. PubMed ID: 9863361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
